Literature DB >> 7929849

Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol.

A J Mendez1, G M Anantharamaiah, J P Segrest, J F Oram.   

Abstract

Clearance of excess cholesterol from cells by HDL is facilitated by the interaction of HDL apolipoproteins with cell-surface binding sites or receptors, a process that may be important in preventing atherosclerosis. In this study, synthetic peptides containing 18-mer amphipathic helices of the class found in HDL apolipoproteins (class A) were tested for their abilities to remove cholesterol and phospholipid from cultured sterol-laden fibroblasts and macrophages and to interact with cell-surface HDL binding sites. Lipid-free peptides containing two identical tandem repeats of class A amphipathic helices promoted cholesterol and phospholipid efflux from cells and depleted cellular cholesterol accessible for esterification by acyl CoA/cholesterol acyltransferase, similar to what was observed for purified apolipoprotein A-I. Peptide-mediated removal of plasma membrane cholesterol and depletion of acyl CoA/cholesterol acyltransferase-accessible cholesterol appeared to occur by separate mechanisms, as the latter process was less dependent on extracellular phospholipid. The dimeric amphipathic helical peptides also competed for high-affinity HDL binding sites on cholesterol-loaded fibroblasts and displayed saturable high-affinity binding to the cell surface. In contrast, peptides with a single helix had little or no ability to remove cellular cholesterol and phospholipid, or to interact with HDL binding sites, suggesting that cooperativity between two or more helical repeats is required for these activities. Thus, synthetic peptides comprising dimers of a structural motif common to exchangeable apolipoproteins can mimic apolipoprotein A-I in both binding to putative cell-surface receptors and clearing cholesterol from cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7929849      PMCID: PMC295333          DOI: 10.1172/JCI117515

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Methods for studying the platelet-derived growth factor receptor.

Authors:  D F Bowen-Pope; R Ross
Journal:  Methods Enzymol       Date:  1985       Impact factor: 1.600

3.  Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition.

Authors:  J L Goldstein; Y K Ho; S K Basu; M S Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1979-01       Impact factor: 11.205

4.  The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations.

Authors:  D W Bilheimer; S Eisenberg; R I Levy
Journal:  Biochim Biophys Acta       Date:  1972-02-21

5.  Effect of end group blockage on the properties of a class A amphipathic helical peptide.

Authors:  Y V Venkatachalapathi; M C Phillips; R M Epand; R F Epand; E M Tytler; J P Segrest; G M Anantharamaiah
Journal:  Proteins       Date:  1993-04

6.  Regulation of high density lipoprotein receptor activity in cultured human skin fibroblasts and human arterial smooth muscle cells.

Authors:  J F Oram; E A Brinton; E L Bierman
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

7.  Studies of synthetic peptide analogs of the amphipathic helix. Effect of charged amino acid residue topography on lipid affinity.

Authors:  P Kanellis; A Y Romans; B J Johnson; H Kercret; R Chiovetti; T M Allen; J P Segrest
Journal:  J Biol Chem       Date:  1980-12-10       Impact factor: 5.157

8.  Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine.

Authors:  G M Anantharamaiah; J L Jones; C G Brouillette; C F Schmidt; B H Chung; T A Hughes; A S Bhown; J P Segrest
Journal:  J Biol Chem       Date:  1985-08-25       Impact factor: 5.157

9.  Studies of synthetic peptide analogs of the amphipathic helix. Correlation of structure with function.

Authors:  B H Chung; G M Anatharamaiah; C G Brouillette; T Nishida; J P Segrest
Journal:  J Biol Chem       Date:  1985-08-25       Impact factor: 5.157

10.  Binding of high density lipoprotein to cultured fibroblasts after chemical alteration of apoprotein amino acid residues.

Authors:  E A Brinton; J F Oram; C H Chen; J J Albers; E L Bierman
Journal:  J Biol Chem       Date:  1986-01-05       Impact factor: 5.157

View more
  39 in total

Review 1.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Oral administration of L-mR18L, a single domain cationic amphipathic helical peptide, inhibits lesion formation in ApoE null mice.

Authors:  Shaila P Handattu; Geeta Datta; Richard M Epand; Raquel F Epand; Mayakonda N Palgunachari; Vinod K Mishra; Candyce E Monroe; Tamara D Keenum; Manjula Chaddha; G M Anantharamaiah; David W Garber
Journal:  J Lipid Res       Date:  2010-09-14       Impact factor: 5.922

3.  Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents.

Authors:  David O Osei-Hwedieh; Marcelo Amar; Dmitri Sviridov; Alan T Remaley
Journal:  Pharmacol Ther       Date:  2010-12-21       Impact factor: 12.310

4.  Structure/function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein.

Authors:  Wilissa D'Souza; John A Stonik; Andrew Murphy; Steven J Demosky; Amar A Sethi; Xiao L Moore; Jaye Chin-Dusting; Alan T Remaley; Dmitri Sviridov
Journal:  Circ Res       Date:  2010-05-27       Impact factor: 17.367

Review 5.  Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review.

Authors:  C Roger White; David W Garber; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2014-08-25       Impact factor: 5.922

Review 6.  HDL therapy for cardiovascular diseases: the road to HDL mimetics.

Authors:  C Roger White; Geeta Datta; Zhenghao Zhang; Himanshu Gupta; David W Garber; Vinod K Mishra; Mayakonda N Palgunachari; Shaila P Handattu; Manjula Chaddha; G M Anantharamaiah
Journal:  Curr Atheroscler Rep       Date:  2008-10       Impact factor: 5.113

Review 7.  Multiple indications for anti-inflammatory apolipoprotein mimetic peptides.

Authors:  Brian J Van Lenten; Mohamad Navab; G M Anantharamaiah; Georgette M Buga; Srinivasa T Reddy; Alan M Fogelman
Journal:  Curr Opin Investig Drugs       Date:  2008-11

8.  Vasculoprotective Effects of Apolipoprotein Mimetic Peptides: An Evolving Paradigm In Hdl Therapy (Vascular Disease Prevention, In Press.).

Authors:  C Roger White; Geeta Datta; Paulina Mochon; Zhenghao Zhang; Ollie Kelly; Christine Curcio; Dale Parks; Mayakonda Palgunachari; Shaila Handattu; Himanshu Gupta; David W Garber; G M Anantharamaiah
Journal:  Vasc Dis Prev       Date:  2009-01-01

9.  Diabetes reduces the cholesterol exporter ABCA1 in mouse macrophages and kidneys.

Authors:  Chongren Tang; Jenny E Kanter; Karin E Bornfeldt; Renee C Leboeuf; John F Oram
Journal:  J Lipid Res       Date:  2009-11-23       Impact factor: 5.922

10.  The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport.

Authors:  Constanze Bergt; Subramaniam Pennathur; Xiaoyun Fu; Jaeman Byun; Kevin O'Brien; Thomas O McDonald; Pragya Singh; G M Anantharamaiah; Alan Chait; John Brunzell; Randolph L Geary; John F Oram; Jay W Heinecke
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.